Accordingly, this study aimed to evaluate the frequency of RUNX1 (Exon 8) and ASXL1 (Exon 12) mutations, as the most common exon sites of mutations, and investigate the survival of AML patients with and without mutations. This evidence concerns the gene RUNX1 and acute myeloid leukemia.